参考文献/References:
［1］ HASSANNIA B,VANDENABEELE P,VANDEN BERGHE T.Targeting ferroptosis to iron out cancer［J］.Cancer Cell,2019,35(6):830-849.
［2］ DIXON S J,LEMBERG K M,LAMPRECHT M R,et al.Ferroptosis:an iron-dependent form of nonapoptotic cell death［J］.Cell，2012，149(5):1060-1072.
［3］ FLORES-ROMERO H,ROS U,GARCA-SEZ A J.A lipid perspective on regulated cell death［J］.Int Rev Cell Mol Biol,2020,351:197-236.
［4］ DOLMA S,LESSNICK S L,HAHN W C,et al.Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells［J］.Cancer Cell,2003,3(3):285-296.
［5］ YANG W S,STOCKWELL B R.Synthetic lethal screening identifies compounds activating iron-dependent,nonapoptotic cell death in oncogenic-RAS-harboring cancer cells ［J］.Chem Biol,2008,15(3):234-245.
［6］ YAGODA N,VON RECHENBERG M,ZAGANJOR E,et al.RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels［J］.Nature,2007，447(7146):865-869.
［7］ DOLL S,CONRAD M.Iron and ferroptosis:a still ill-defined liaison［J］.IUBMB Life,2017,69(6) :423-434.
［8］ GALLUZZI L,VITALE I,AARONSON S A,et al.Molecular mechanisms of cell death:recommendations of the Nomenclature Committee on Cell Death［J］.Cell Death Differ,2018,25(3):486-541.
［9］ XIE Y,HOU W,SONG X,et al.Ferroptosis:process and function［J］.Cell Death Differ,2016,23(3):369-379.
［10］ HAN C,LIU Y,DAI R,et al.Ferroptosis and its potential role in human diseases［J］.Front Pharmacol,2020,17(11):239.
［11］ GALARIS D,BARBOUTI A,PANTOPOULOS K.Iron homeostasis and oxidative stress:an intimate relationship［J］.Biochim Biophys Acta Mol Cell Res,2019,1866(12):118535.
［12］ SHAIKH H,FAISAL M S,MEWAWALLA P.Vitamin C deficie-ncy:rare cause of severe anemia with hemolysis［J］.Int J Hematol,2019,109(5):618-621.
［13］ WU L,DING Q,WANG X,et al.Visualization of dynamic changes in labile iron(II) pools in endoplasmic reticulum stress-mediated drug-induced liver injury［J］.Anal Chem,2020,92(1):1245-1251.
［14］ HANSON E H,IMPERATORE G,BURKE W.HFE gene and hereditary hemochromatosis——a HuGE review［J］.Am J Epidemiol,2001,154(3):193-206.
［15］ GABUTTI V,PIGA A.Results of long-term iron-chelating therapy［J］.Acta Haematol,1996,95(1):26-36.
［16］ ROMAN M J,SHANKER B A,DAVIS A.Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus［J］.N Engl J Med,2003,349(25)2399-2406.
［17］ MACAS-RODRGUEZ R U,INZAUGARAT M E,RUIZ-MARGIN A,et al.Reclassifying hepatic cell death during liver damage:ferroptosis——a novel form of non-apoptotic cell death［J］.Int J Mol Sci,2020,21(5):1651.
［18］ BAYIR H,ANTHONYMUTHU T S,TYURINA Y Y,et al.Achieving life through death:redox biology of lipid peroxidation in ferroptosis［J］.Cell Chem Biol,2020,27(4):387-408.
［19］ WALLACE Z,SPECKS U,HOFFMAN G,et al.SAT0370 antineutrophil cytoplasmic antibody (ANCA) type and body mass index in anca-associated vasculitis［J］.Ann Rheum,2016,75(2):800-801.
［20］ BASHEY A,ZHANG X,SIZEMORE C A,et al.T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation［J］.J Clin Oncol,2013,31(10):1310-1316.
［21］ TORII S,SHINTOKU R,KUBOTA C,et al.An essential role for functional lysosomes in ferroptosis of cancer cells［J］.Biochem J,2016,473(6):769-777.
［22］ NIE J,LIN B,ZHOU M,et al.Role of ferroptosis in hepatocellular carcinoma［J］.J Cancer Res Clin Oncol,2018,144(12):2329-2337.
［23］ LOUANDRE C,EZZOUKHRY Z,GODIN C,et al.Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib［J］.Int J Cancer,2013,133(7):1732-1742.
［24］ ZHU Y J,ZHENG B,WANG H Y,et al.New knowledge of the mechanisms of sorafenib resistance in liver cancer［J］.Acta Pharmacol Sin,2017,38(5):614-622.
［25］ SU Y,ZHAO B,ZHOU L,et al.Ferroptosis,a novel pharmacological mechanism of anti-cancer drugs［J］.Cancer Letters,2020,483(28):127-136.
［26］ LACHAIER E,LOUANDRE C,GODIN C,et al.Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors［J］.Anticancer Res,2014,34(11):6417-6422.
［27］ CAPELLETTI M M,MANCEAU H,PUY H,et al.Ferroptosis in liver diseases:an overview［J］.Int J Mol Sci,2020,21(14):4908.
［28］ HIRAYAMA T,MIKI A,NAGASAWA H.Organelle-specific analysis of labile Fe(II) during ferroptosis by using a cocktail of various colour organelle-targeted fluorescent probes［J］.Metallomics,2019,11(1):111-117.
［29］ YANG R,SONG C,CHEN J,et al.Limonin ameliorates acetami-nophen-induced hepatotoxicity by activating Nrf2 antioxidative pathway and inhibiting NF-κB inflammatory response via upregulating Sirt1［J］.Phytomedicine,2020,69(4):153211.
［30］ GUM S I,CHO M K.Recent updates on acetaminophen hepatotoxicity:the role of Nrf2 in hepatoprotection［J］.Toxicol Res,2013,29(3):165-172.
［31］ BISHAYEE A,BHATIA D,THOPPIL R J,et al.Pomegranate-mediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms［J］.Carcinogenesis,2011,32(6):888-896.
［32］ JIANG L,KON N,LI T,et al.Ferroptosis as a p53-mediated activity during tumour suppression［J］. Nature,2015,520(7545):57-62.
［33］ SID B,GLORIEUX C,VALENZUELA M,et al.AICAR induces Nrf2 activation by an AMPK-independent mechanism in hepatocarcinoma cells［J］.Biochem Pharmacol,2014,91(2):168-180.
［34］ WANG S J,OU Y,JIANG L,et al.Ferroptosis:a missing puzzle piece in the p53 blueprint［J］.Mol Cell Oncol,2016,3(3):e1046581.
［35］ JENNIS M,KUNG C P,BASU S,et al.An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model［J］.Genes Dev,2016,30(8):918-930.
［36］ REINBOLD M,LUO J L,NEDELKO T,et al.Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72［J］.Oncogene,2008,27(19):2788-2794.
［37］ SHI Z Z,FAN Z W,CHEN Y X,et al.Ferroptosis in carcinoma:regulatory mechanisms and new method for cancer therapy［J］.Onco Targets Ther,2019,12(11):11291-11304.
［38］ GAO M,MONIAN P,QUADRI N,et al.Glutaminolysis and transferrin regulate ferroptosis［J］.Mol Cell,2015,59(2):298-308.
［39］ KNUDSEN E S,KNUDSEN K E.Tailoring to RB:tumour suppressor status and therapeutic response［J］.Nat Rev Cancer,2008,8(9):714-724.
［40］ MAYHEW C N,CARTER S L,FOX S R,et al.RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis［J］.Gastroenterology,2007,133(3):976-984.
［41］ LOUANDRE C,MARCQ I,BOUHLAL H,et al.The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells［J］.Cancer Letters,2015,356(2 Pt B):971-977.
［42］ YUAN H,LI X,ZHANG X,et al.CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation［J］.Biochem Biophys Res Commun,2016,478(2):838-844.
［43］ ANANDHAN A,DODSON M,SCHMIDLIN C J,et al.Breakdown of an ironclad defense system:the critical role of NRF2 in mediating ferroptosis［J］.Cell Chem Biol,2020,27(4):436-447.
［44］ LIU J,LIU Y,MENG L,et al.Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma［J］.Oncol Rep,2017,38(2):899-907.
［45］ HOUESSINON A,FRANOIS C,SAUZAY C,et al.Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib［J］.Mol Cancer,2016,15(1):38.
［46］ CHEN J ,WO D ,MA E ,et al.Deletion of low-density lipoprotein-related receptor 5 inhibits liver cancer cell proliferation via destabilizing nucleoporin 37［J］.Cell Commun Signal,2019,17(1):174.
［47］ OU W,MULIK R S,ANWAR A,et al.Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma［J］.Free Radic Biol Med,2017,112(1):597-607.
［48］ HAYES J D,MCLELLAN L I.Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress［J］.Free Radic Res,1999，31(4):273-300.
［49］ CHEN W C,WANG C Y,HUNG Y H,et al.Systematic analysis of gene expression alterations and clinical outcomes for long-chain acyl-coenzyme a synthetase family in cancer［J］.PLoS One,2016,11(5):e0155660.
［50］ DIXON S J,PATEL D N,WELSCH M,et al.Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reti-culum stress and ferroptosis［J］.Elife,2014,3:e2523.
［51］ SUN X,OU Z,CHEN R,et al.Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells［J］.Hepatology,2016,63(1):173-184.
［52］ YAMADA N,KOMADA T,OHNO N,et al.Acetaminophen-induced hepatotoxicity:different mechanisms of acetaminophen-induced ferroptosis and mitochondrial damage［J］.Arch Toxicol,2020,94(6):2255-2257.
［53］ LRINCZ T,JEMNITZ K,KARDON T,et al.Ferroptosis is involved in acetaminophen induced cell death［J］.Pathol Oncol Res,2015,21(4):1115-1121.
［54］ 何银，刘春雨，何迟迟，等.扶正养肝合剂对药物性肝损伤的保护作用研究［J］.中国中药杂志,2018,43(23):4685-4691.
［55］ YAMADA N,KARASAWA T,TAKAHASHI M.Role of ferroptosis in acetaminophen-induced hepatotoxicity［J］.Arch Toxicol,2020,94(5):1769-1770.
［56］ ERHARDT D P,CANNON G W,TENG C C,et al.Low persistence rates in patients with rheumatoid arthritis treated with triple therapy and adverse drug events associated with sulfasalazine［J］.Arthritis Care Res (Hoboken),2019,71(10):1326-1335.
［57］ VIOLA A,CALTAGIRONE A M,CAMPISI G,et al.Stevens-Johnson syndrome on treatment with sulfasalazine for Crohns disease:need for a multidisciplinary approach［J］.Turk J Gastroenterol,2019,30(2):211-212.
［58］ CONRAD M,PRONETH B.Selenium:tracing another essential element of ferroptotic cell death［J］.Cell Chem Biol,2020,27(4):409-419.
［59］ LIANG C,ZHANG X,YANG M,et al.Recent progress in ferro-ptosis inducers for cancer therapy［J］.Adv Mater,2019,31(51):e1904197
［60］ YU H,YANG C,JIAN L,et al.Sulfasalazine-induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor［J］.Oncology Reports,2019,42(2):826-838.
［61］ GUO W,ZHAO Y,ZHANG Z,et al.Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma［J］.Cancer Lett,2011,312(1):55-61.
［62］ DHINGRA V,VISHWESHWAR RAO K,LAKSHMI NARASU M.Current status of artemisinin and its derivatives as antimalarial drugs［J］.Life Sci,2000,66(4):279-300.
［63］ ZHOU H J,ZHANG J L,LI A,et al.Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro［J］.Cancer Chemother Pharmacol,2010,66(1):21-29.
［64］ ZHU S,YU Q,HUO C,et al.Ferroptosis:a novel mechanism of artemisinin and its derivatives in cancer therapy［J］.Curr Med Chem,2020.DOI:10.2174/0929867327666200121124404.Epub ahead of print.
［65］ YANG N D,TAN S H,NG S,et al.Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin［J］.J Biol Chem,2014,289(48):33425-33441.
［66］ CHEN G Q,BENTHANI F A,WU J,et al.Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis［J］.Cell Death Differ,2020,27(1):242-254.
［67］ 李艳纯,周怡,王鑫,等.二氢青蒿素通过诱导铁死亡抑制肝癌细胞生长［J］.中国生物化学与分子生物学报,2019,35(12):1361-1366.
［68］ JO Y S,KIM M S,YOO N J,et al.Somatic Mutations and intratumoral heterogeneity of MYH11 gene in gastric and colorectal cancers［J］.Appl Immunohistochem Mol Morphol,2018,26(8):562-566.
［69］ HOU C,GUO D,YU X,et al.TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib［J］.Biomed Pharmacother,2020,126(9):109862.